Atlas Trials

A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.

Clinical trial NCT02034006 · COMPLETED

Trial details

NCT number
NCT02034006
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Choroidal Neovascularization Secondary to Pathologic Myopia
Start date
2014-06-10
Primary completion
2016-07-15
Enrollment
200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.